Fenimore Asset Management Inc. Has $11.17 Million Holdings in Natus Medical Inc (NASDAQ:BABY)

Fenimore Asset Management Inc. grew its stake in Natus Medical Inc (NASDAQ:BABY) by 11.2% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 434,900 shares of the medical equipment provider’s stock after buying an additional 43,735 shares during the quarter. Fenimore Asset Management Inc. owned 1.28% of Natus Medical worth $11,173,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in BABY. First Trust Advisors LP lifted its position in shares of Natus Medical by 100.0% in the first quarter. First Trust Advisors LP now owns 83,988 shares of the medical equipment provider’s stock valued at $2,132,000 after acquiring an additional 42,003 shares in the last quarter. Marshall Wace LLP purchased a new stake in shares of Natus Medical in the first quarter valued at $2,295,000. Sapience Investments LLC lifted its position in shares of Natus Medical by 12.7% in the first quarter. Sapience Investments LLC now owns 302,120 shares of the medical equipment provider’s stock valued at $7,668,000 after acquiring an additional 34,060 shares in the last quarter. WCM Investment Management LLC lifted its position in shares of Natus Medical by 68.8% in the first quarter. WCM Investment Management LLC now owns 403,183 shares of the medical equipment provider’s stock valued at $10,233,000 after acquiring an additional 164,313 shares in the last quarter. Finally, AlphaCrest Capital Management LLC purchased a new stake in shares of Natus Medical in the first quarter valued at $355,000. Institutional investors and hedge funds own 91.56% of the company’s stock.

Several research firms recently weighed in on BABY. Zacks Investment Research upgraded Natus Medical from a “strong sell” rating to a “hold” rating in a research report on Wednesday, June 26th. TheStreet lowered Natus Medical from a “c-” rating to a “d+” rating in a research note on Thursday, April 25th. BidaskClub upgraded Natus Medical from a “strong sell” rating to a “sell” rating in a research note on Tuesday, July 23rd. Finally, ValuEngine lowered Natus Medical from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and one has given a buy rating to the company. Natus Medical presently has an average rating of “Hold” and an average target price of $36.00.

In other news, VP Dong Chune Christopher Chung sold 3,500 shares of the firm’s stock in a transaction on Tuesday, May 21st. The stock was sold at an average price of $26.33, for a total value of $92,155.00. Following the completion of the sale, the vice president now owns 154,398 shares of the company’s stock, valued at $4,065,299.34. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ken Ludlum sold 4,250 shares of the firm’s stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $24.41, for a total value of $103,742.50. Following the completion of the sale, the director now directly owns 46,192 shares of the company’s stock, valued at approximately $1,127,546.72. The disclosure for this sale can be found here. Insiders sold a total of 46,382 shares of company stock worth $1,371,204 over the last 90 days. Insiders own 1.65% of the company’s stock.

NASDAQ:BABY opened at $31.92 on Friday. The company has a market cap of $1.09 billion, a PE ratio of 22.48 and a beta of 0.57. Natus Medical Inc has a 52 week low of $23.53 and a 52 week high of $37.90. The company has a quick ratio of 1.18, a current ratio of 1.70 and a debt-to-equity ratio of 0.18. The business’s 50 day moving average is $28.00 and its two-hundred day moving average is $26.89.

Natus Medical (NASDAQ:BABY) last announced its earnings results on Thursday, July 25th. The medical equipment provider reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.30 by $0.04. The firm had revenue of $125.50 million for the quarter, compared to the consensus estimate of $122.85 million. Natus Medical had a positive return on equity of 10.79% and a negative net margin of 7.38%. The firm’s revenue for the quarter was down 4.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.35 EPS. As a group, sell-side analysts expect that Natus Medical Inc will post 1.27 EPS for the current fiscal year.

Natus Medical Company Profile

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders.

Read More: Death Cross

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.